Chief Operating Officer
Fredrik Wiklund has over 20 years of biopharmaceutical experience and currently serves as our Chief Operating Officer. Prior to this role, Fred served as President and Chief Executive Officer of Celladon Corporation (CLDN), a publicly traded biotechnology company, having previously served as its Vice President, Corporate Development and Investor Relations. During his time at Celladon, Fred lead the company through its Initial Public Offering (IPO) and eventual merger with Eiger Biopharmaceuticals. Prior to Celladon, Fred served as Head of Corporate Development and Investor Relations at Tercica, Inc (TRCA). At his 5 years at Tercica, Fred assisted in the company’s IPO and also completed strategic transactions exceeding $800M, including the company’s sale to the Ipsen Group in 2008. Previously, Fred was an investment banker with Lehman Brothers where he assisted both pharmaceutical and emerging biotechnology companies complete capital-raising and strategic transactions. Fred also has over 7 years of commercial experience, primarily with Gilead Sciences where he participated in the company’s first product launch in 1996. Mr. Wiklund received his M.B.A. from the University of Southern California and his B.A. from the University of San Diego.